Suzanne Kamel-Reid, PhD

Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Keywords: leukemia, head and neck cancers, comparative genomic hybridization (CGH), spectral karyotyping, lovastatin, acute promyelocytic leukemia (APL)
Identifying biomarkers of cancer initiation, progression and recurrence

Work in my laboratory focuses on the application of high throughput technologies (e.g., gene expression microarrays, tissue arrays, ChIP-on-chip, microRNA arrays, protein arrays) to enhance our understanding of cancer biology. Specifically, we are interested in identifying biomarkers of cancer initiation, progression and recurrence in two types of human cancer: head and neck squamous cell carcinoma (HNSCC) and acute promyelocytic leukemia (APL).
  • Head and neck squamous cell carcinoma
    In this arm of my research laboratory, we are specifically interested in the etiology of oral cancers (OSCCs). The molecular genetic changes involved in oral cancer development are poorly understood. Our work focuses on three major questions:
    1. What are the gene(s) involved in recurrence of oral cancer? Approximately 50% of OSCCs recur after surgery. Our current approaches involve analyzing OSCC tumour samples, as well as samples taken from the regions immediately surrounding the tumours at time of surgery (''surgical resection margins'') in order to identify genes deregulated in the tumour and in the surrounding margin(s), which may be predictive of tumour recurrence.
    2. What are the steps involved in the development of oral cancer? A significant fraction of OSCCs arise from precursor lesions called leukoplakias. In these studies, we are interested in profiling the genetic changes—specifically, changes in microRNA expression—in leukoplakias and comparing them to genetic changes found in tumours.
    3. What are the underlying genetic differences between OSCCs in young patients (<45 yrs of age) and older patients (>45 yrs of age)? OSCCs are strongly associated with the risk factors of alcohol consumption and smoking tobacco. However, younger patients who do not exhibit exposure to either of these two risk factors are still diagnosed with OSCC. Our previous work has demonstrated that genetic differences exist between young and older patients. Specifically, we have observed defective DNA mismatch repair and differential gene expression in young patients compared to older patients. This line of study is aimed at further understanding the genetic differences between young and older patients, and at understanding the role of defective DNA repair in OSCCs.
  • Acute promyelocytic leukemia
    Leukemias are often associated with chromosomal translocations that give rise to fusion proteins which may deregulate cellular signaling or transcription. Our group cloned and characterized two variant fusion proteins involved in acute promyelocytic leukemia (APL), NPM-RAR-alpha and NuMA-RAR-alpha, which are both aberrant transcription factors; we are especially interested in understanding the roles of these fusion proteins in the cell. Specifically, we use cell lines, mouse models and human patient samples in order to understand leukemia biology. The questions we are most interested in include:
    1. What are the cell biology effects of the APL fusion proteins? While most studies have focused on the APL fusions as transcription factors, more recent evidence has suggested that these proteins behave distinctly and have effects through protein-protein interactions on other signaling pathways within the leukemic cell. We are applying the same concept as above, and hypothesizing that there may be a common set of interactions and/or deregulated pathways shared by all APL fusion proteins, and are characterizing the protein-protein interactions of the fusions in order to find this out.
    2. What are the necessary secondary events in leukemia development? Previous studies have indicated that the APL fusions are necessary, but insufficient, for the development of leukemia in mice. This suggests that additional genetic ''events'' may cooperate with the fusions in leukemia. We are addressing this question through the above studies, and also through genetic studies of the hCG-NuMA-RAR-alpha mouse model that we previously developed and characterized.
    What are the common downstream genetic targets of the APL fusion proteins? APL is associated with seven known fusion proteins, all of which involve the RAR-alpha transcription factor. Yet, all fusion proteins give rise to the same disease. We hypothesize that this is because all fusion proteins have a common set of direct transcriptional targets, and are utilizing gene expression arrays and ChIP-on-chip technology to address this issue.
Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
Blood Adv. 2019 Aug 13;3(15):2307-2311
Murphy T, Zou J, Daher-Reyes GS, Arruda A, Gupta V, McNamara CJ, Minden MD, Schimmer AD, Sibai H, Yee KWL, Korulla M, Stockley T, Kamel-Reid S, Maze D, Tierens A, Bratman SV, Schuh AC, Chan SM
HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors.
Int J Gynecol Pathol. 2019 Jul 03;:
Allo G, Yap ML, Cuartero J, Milosevic M, Ferguson S, Mackay H, Kamel-Reid S, Weinreb I, Ghazarian D, Pintilie M, Clarke BA
Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee.
Arch Pathol Lab Med. 2019 Apr 10;:
Moncur JT, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Kim AS
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Gynecol Oncol. 2019 Feb 18;:
Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Clin Lung Cancer. 2018 Dec 19;:
Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA
Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels.
J Mol Diagn. 2018 Dec 18;:
Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL
Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
J Pathol Clin Res. 2018 Nov 01;:
McCarthy AJ, Capo-Chichi JM, Spence T, Grenier S, Stockley T, Kamel-Reid S, Serra S, Sabatini P, Chetty R
Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.
Arch Pathol Lab Med. 2018 Oct 30;:
Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, Montgomery SB, Nagarajan R, Portier BP, Routbort MJ, Smail C, Surrey LF, Vasalos P, Lazar AJ, Lindeman NI
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.
Blood Adv. 2018 Oct 23;2(20):2658-2671
McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V
Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms.
Blood. 2018 Sep 24;:
Kennedy JA, Medeiros JJF, Dobson SM, Arruda A, Sukhai MA, Stockley T, Tierens A, Minden MD, Kamel-Reid S, Dick JE, Gupta V

Pages


 
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre

Professor, Departments of Medical Biophysics and Laboratory Medicine and Pathobiology, University of Toronto
Head, Laboratory Genetics, University Health Network
Director, Molecular Diagnostics, University Health Network
Member, Ontario Genetics Secretariat Executive
Co-chair, Molecular Oncology Advisory Committee, Cancer Care Ontario​